Loading company…
Vasa Therapeutics develops therapies targeting cardiovascular aging and related diseases.
Founded in 2019 in California by CEO Artur Plonowski, Vasa Therapeutics develops therapies for cardiovascular aging, heart failure, peripheral artery disease, and sarcopenia. Its programs include VS-041 for heart failure with preserved ejection fraction, apelin peptide analogs, and a camKIId inhibitor. In January 2024, the company raised USD 2.3 million in grant funding to advance therapies for cardiovascular disease.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in